TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ikena Oncology ( (IKNA) ) has provided an announcement.
On July 11, 2025, Ikena Oncology announced that Institutional Shareholder Services and Glass, Lewis & Co. have recommended that stockholders vote in favor of the proposed merger with Inmagene Biopharmaceuticals at the upcoming Annual Meeting of Stockholders on July 15, 2025. This merger is expected to enhance Ikena’s position in the immunological and inflammatory disease space, leveraging Inmagene’s lead asset, IMG-007, which has shown promising results in clinical trials. The merger is anticipated to bring value to shareholders and strengthen the combined company’s market position.
The most recent analyst rating on (IKNA) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Ikena Oncology stock, see the IKNA Stock Forecast page.
Spark’s Take on IKNA Stock
According to Spark, TipRanks’ AI Analyst, IKNA is a Neutral.
Ikena Oncology’s overall stock score of 41.2 reflects significant challenges in financial performance, including declining revenues and negative cash flow, which weigh heavily on the score. Technical analysis shows lackluster momentum, while the valuation is unattractive due to negative earnings. Improvements in revenue generation and profitability are crucial for a better financial outlook.
To see Spark’s full report on IKNA stock, click here.
More about Ikena Oncology
Ikena Oncology is a company that develops differentiated therapies targeting cancer growth, spread, and therapeutic resistance. The company aims to efficiently develop the right drug using the right modality for the right patient. Inmagene Biopharmaceuticals is a global clinical-stage biotechnology company focused on developing novel therapeutics for immunological and inflammatory diseases, with a lead asset, IMG-007, in clinical trials for atopic dermatitis.
Average Trading Volume: 88,762
Technical Sentiment Signal: Sell
Current Market Cap: $64.67M
For an in-depth examination of IKNA stock, go to TipRanks’ Overview page.